This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Inogen (INGN) Stock Surges 16.5% Despite Q4 Earnings Miss
by Zacks Equity Research
Inogen's (INGN) fourth-quarter results benefit from higher revenues across the majority of its geographical segments.
Inogen (INGN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of -36.49% and 0.04%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Avanos Medical (AVNS) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 15% and 1.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Inogen (INGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Inogen (INGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inogen's (INGN) Preliminary Q4 Revenues Solid Amid Challenges
by Zacks Equity Research
Inogen's (INGN) revenue growth in the fourth quarter is likely to have been boosted by solid product sales despite supply chain constraints.
Inogen (INGN) Earnings and Revenues Surpass Estimates in Q3
by Zacks Equity Research
Inogen's (INGN) third-quarter results benefit from higher revenues across its segments.
Inogen (INGN) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 282.76% and 9.04%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Inogen (INGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Inogen (INGN) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.
Inogen (INGN) Stock Loses 26.7% In Spite of Q2 Earnings Beat
by Zacks Equity Research
Inogen's (INGN) second-quarter results benefit from higher revenues across its segments.
Inogen (INGN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 269.23% and 15.22%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Inogen (INGN) Q2 Earnings Expected to Decline
by Zacks Equity Research
Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inogen (INGN) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Inogen's (INGN) direct-to-customer business model and a strong product portfolio.
Here's Why You Should Buy National Vision (EYE) Stock Now
by Zacks Equity Research
Investors remain optimistic about National Vision (EYE) on increased eyeglass comparable demand and encouraging 2021 strategies.
Top Ranked Momentum Stocks to Buy for June 29th
by Zacks Equity Research
AMN, INGN, SWBI, and CMRE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 29, 2021
LabCorp (LH), Molecular Loop Team Up for COVID-19 Test Research
by Zacks Equity Research
The SARS-CoV-2 Research Sequencing Panel will help LabCorp (LH) sequence thousands of complete coronavirus genomes each week from positive patient samples.
Hologic (HOLX) Gets European Nod for Aptima CMV Quant Assay
by Zacks Equity Research
Hologic's (HOLX) Aptima CMV Quant assay is intended to help in the diagnosis and management of solid-organ transplant patients and hematopoietic stem cell transplant patients.
Here's Why You Should Add Inogen (INGN) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its direct-to-customer business model and a strong product portfolio.
Quest Diagnostics (DGX) Unveils Corporate Responsibility Report
by Zacks Equity Research
Per Quest Diagnostics' (DGX) 2020 Corporate Responsibility Report, it has expanded COVID-19 capacity throughout the year, performing 30 million COVID-19 molecular tests and serology tests.
Medtronic (MDT) Gets Expanded FDA Nod for Cryoablation Catheters
by Zacks Equity Research
Medtronic's (MDT) Cardiac Cryoablation Catheters offer safe and effective substitute to antiarrhythmic drug therapy for the prevention of atrial arrythmia recurrence.
Here's Why You Should Add Henry Schein (HSIC) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Henry Schein (HSIC) on its extensive global foothold and bullish 2021 earnings guidance.
Abbott's (ABT) Base Business Recovers, Lowered View Concerns
by Zacks Equity Research
According to Abbott (ABT), significant reductions in the number of COVID-19 cases in the United States and other major developed countries to hamper demand for COVID-19 testing in 2021.
Thermo Fisher's (TMO) New Launch Boosts Preclinical Development
by Zacks Equity Research
Thermo Fisher's (TMO) enhanced Quick to Clinic solution provides balance of speed and quality to accelerate and advance DNA to Investigational New Drug in as less as 13 months.
Bruker (BRKR) Updates 2021 Outlook, Issues Medium-Term View
by Zacks Equity Research
Bruker (BRKR) updates 2021 financial guidance encouraged by solid business growth and high-growth opportunities.
Phirbo (PAHC) Nutritional Specialties Grow, Vaccine Sales Dip
by Zacks Equity Research
Currently, Phirbo (PAHC) is focused on expanding its footprint in the poultry, swine and cattle industries, in both domestic and international markets.